33.8 C
Delhi
Friday, July 4, 2025

Alembic Pharma receives USFDA final approval for Prazosin Hydrochloride Capsules

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Pharma major, Alembic Pharma on Wednesday said it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Minipress Capsules, 1 mg, 2 mg, and 5 mg, of Pfizer Inc. Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure. Refer to our label for full indication.

Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg have an estimated market size of US$ 50 million for twelve months ending Dec 2022, according to IQVIA.

Related articles

Bharat’s Trailblazing Renaissance in Energy Transition

“The world is looking up to India. Those who saw India as slow and steady, can now see...

When Rivers Remember: India’s Ganga Gambit in the Shadow of the Indus Waters Treaty

In the small riverside town of Rajshahi in Bangladesh, 58-year-old farmer Abdul Momen wakes at dawn, not to...

Ditch the Spoon and Fork: Embrace the Indian Way of Eating with Your Fingers

 In an age where we’ve outsourced even our chewing to convenience, where children eat pizza with a fork...

After Delhi’s Yash Kumar Murder, Victim’s Family Receive Death Threats

In yet another tragic incident that sent shockwaves around the national capital and beyond, 20-year-old Yash Kumar was...